A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: R 1 is C 1-8 alkyl, or C 3-12 carbocycle; and wherein the aliphatic and aromatic portions of R 1 are optionally substituted with -(X 1R) 0-1 OR R1a, wherein X 1R is selected from the group consisting of C 1-4 alkylene, C 1-4 heteroalkylene, C 2-4 alkenylene and C 2-4 alkynylene; wherein R R1a is selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-8 haloalkyl, C 3-8 carbocycle, phenyl, benzyl, C 5-6 heteroaryl and C 2-7 heterocycle; R N is hydrogen, C 1-4 alkyl or C 1-4 haloalkyl; R 2 and R 3 are each independently selected from the group consisting of H, F, Cl, Br, I, -CN, C 1-8 alkyl, C 1-8 haloalkyl and C 1-8 alkoxy; R 4 is selected from the group consisting of H, F, Cl, Br, I, -CN, C 1-8 alkyl, C 1-8 haloalkyl, C 1-8 alkoxy, C 3-8 carbocycle, C 2-7 heterocycle, phenyl and 5-6 membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O and S, wherein said 5-6 membered heteroaryl is further optionally substituted with from 1 to 3 R 5 substituents selected from F, Cl, Br, I, -CN, C 1-4 alkyl, C 1-4 haloalkyl and C 1-4 alkoxy; L is a linker selected from the group consisting of C 1-4 alkylene, C 2-4 alkenylene, C 2-4 alkynylene, and C 1-4 heteroalkylene, wherein L is optionally substituted with from 1 to 3 R L substituents selected from the group consisting of =O, C 1-4 alkyl, C 1-4 haloalkyl and C 1-4 acyl; the subscript m represents the integer 0 or 1; X 1 and X 2 are each independently selected from the group consisting of absent, -O-, -S -,-S 2 - and -N(R X)- wherein R x is H, C 1-8 alkyl, C 1-8 acyl or -S 2 (C 1-8 alkyl), and wherein if the subscript m is 0 then one of X 1 or X 2 is absent; the subscript n is an integer from 0 to 5; A is selected from the group consisting of hydrogen, C 3 -C 20 carbocycle, C 3 -C 20 heterocycle, aryl, and heteroaryl, wherein if A is hydrogen then the subscript n is 0; and R A is selected from the group consisting of C 1-8 alkyl, C 1-8 haloalkyl, F, Cl, Br, I, -OH, -CN, -NO 2, heteroaryl, -(X RA) 0-1 OR A1, wherein X RA is selected from the group consisting of C 1-4 alkylene, C 1-4 heteroalkylene, C 2-4 alkenylene and C 2-4 alkynylene; wherein R A1 is hydrogen, C 1-8 alkyl, or C 1-8 haloalkyl. R 1 is C 1-8 alkyl, or C 3-12 carbocycle; and wherein the aliphatic and aromatic portions of R 1 are optionally substituted with -(X 1R) 0-1 OR R1a, wherein X 1R is selected from the group consisting of C 1-4 alkylene, C 1-4 heteroalkylene, C 2-4 alkenylene and C 2-4 alkynylene; wherein R R1a is selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-8 haloalkyl, C 3-8 carbocycle, phenyl, benzyl, C 5-6 heteroaryl and C 2-7 heterocycle; R N is hydrogen, C 1-4 alkyl or C 1-4 haloalkyl; R 2 and R 3 are each independently selected from the group consisting of H, F, Cl, Br, I, -CN, C 1-8 alkyl, C 1-8 haloalkyl and C 1-8 alkoxy; R 4 is selected from the group consisting of H, F, Cl, Br, I, -CN, C 1-8 alkyl, C 1-8 haloalkyl, C 1-8 alkoxy, C 3-8 carbocycle, C 2-7 heterocycle, phenyl and 5-6 membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O and S, wherein said 5-6 membered heteroaryl is further optionally substituted with from 1 to 3 R 5 substituents selected from F, Cl, Br, I, -CN, C 1-4 alkyl, C 1-4 haloalkyl and C 1-4 alkoxy; L is a linker selected from the group consisting of C 1-4 alkylene, C 2-4 alkenylene, C 2-4 alkynylene, and C 1-4 heteroalkylene, wherein L is optionally substituted with from 1 to 3 R L substituents selected from the group consisting of =O, C 1-4 alkyl, C 1-4 haloalkyl and C 1-4 acyl; the subscript m represents the integer 0 or 1; X 1 and X 2 are each independently selected from the group consisting of absent, -O-, -S -,-S 2 - and -N(R X)- wherein R x is H, C 1-8 alkyl, C 1-8 acyl or -S 2 (C 1-8 alkyl), and wherein if the subscript m is 0 then one of X 1 or X 2 is absent; the subscript n is an integer from 0 to 5; A is selected from the group consisting of hydrogen, C 3 -C 20 carbocycle, C 3 -C 20 heterocycle, aryl, and heteroaryl, wherein if A is hydrogen then the subscript n is 0; and R A is selected from the group consisting of C 1-8 alkyl, C 1-8 haloalkyl, F, Cl, Br, I, -OH, -CN, -NO 2, heteroaryl, -(X RA) 0-1 OR A1, wherein X RA is selected from the group consisting of C 1-4 alkylene, C 1-4 heteroalkylene, C 2-4 alkenylene and C 2-4 alkynylene; wherein R A1 is hydrogen, C 1-8 alkyl, or C 1-8 haloalkyl.